CBT is an evidence-based, nonhormonal option endorsed by the National Institutes of Health and The Menopause Society for ...
Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...
Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and ...
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for ...
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC ...
For primary care physicians, the question is increasingly whether continuous glucose data could answer a clinically useful ...
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while ...
The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Natera's multi-cancer early ...
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood ...
The American College of Obstetricians & Gynecologists (ACOG) has published new clinical guidance on managing menopause-related vasomotor symptoms (VMS), sleep disturbance, and moo ...
Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results